ReviewCurrent oncology reports2023
Hairy Cell Leukemia: Where Are We in 2023?
Review in Current oncology reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Guideline
- Hairy cell leukemia in a 51-year-old Syrian male: a case report.International journal of surgery case reports · 2026Article
- Classic Hairy Cell Leukemia and Related Disorders: An Updated Review of Molecular Features and Personalized Therapies.Journal of personalized medicine · 2026Review
- AI-Driven Combination Therapy for Counteracting Dysregulated Genes in Lung Adenocarcinoma: Contribution-Aware Metaheuristic for Drug Repurposing.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Hairy cell leukemia: a chronic B-cell lymphoma with unique clinicopathological features and unresolved molecular mechanisms.Blood advances · 2026Review
- Expression of SLAMF7 on hairy cell leukemia indicates therapy option with SLAMF7-antibody Elotuzumab.Leukemia research reports · 2026Article
- Multiple brain lesions in a patient with relapsed hairy cell leukemia: a case report and review of the literature.CNS oncology · 2025Review
- Evaluation of Clinical Outcomes and Treatment Complications in Hairy Cell Leukemia: A Single-Center Retrospective Analysis.Cancer reports (Hoboken, N.J.) · 2025Article
- Article
- Immune activation and microenvironmental crosstalk in hairy cell leukemia.Frontiers in immunology · 2025Review
- The Molecular Pathology of Blood Cancer: A Comprehensive Review of Chromosome and Genetic Abnormalities and Their Clinical Utility.British journal of biomedical science · 2025Review
- Hairy cell leukemia - etiopathogenesis, diagnosis and modern therapeutic approach.Biochemia medica · 2024Review
- Methylation regulation for FUNDC1 stability in childhood leukemia was up-regulated and facilitates metastasis and reduces ferroptosis of leukemia through mitochondrial damage by FBXL2.Open medicine (Warsaw, Poland) · 2024Article
- Non-canonicalOncology research · 2024Review
- Flow Cytometry of CD5-Positive Hairy Cell Leukemia.Molecular diagnosis & therapy · 2023Article
- Repurposable Drugs for Immunotherapy and Strategies to Find Candidate Drugs.Pharmaceutics · 2023Review
- Broadening the horizon: potential applications of CAR-T cells beyond current indications.Frontiers in immunology · 2023Review
- A case report of early diagnosis of asymptomatic hairy cell leukemia using flow cytometry.Frontiers in immunology · 2023Article
- Educational Case: Hairy cell leukemia.Academic pathologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThis article summarizes the current state of knowledge of hairy cell leukemia (HCL) regarding presentation, diagnosis, therapy, and monitoring, including perspectives on emergent therapies. RECENT
findingsOver the past decade, there has been enormous progress in the understanding of the biology of HCL which has led to the development of novel therapeutic strategies. The maturation of data regarding existing management strategies has also lent considerable insight into therapeutic outcomes and prognosis of patients treated with chemo- or chemoimmunotherapy. Purine nucleoside analogs remain the cornerstone of treatment, and the addition of rituximab has deepened and prolonged responses in the upfront and relapsed setting. Targeted therapies now have a more defined role in the management of HCL, with BRAF inhibitors now having a potential in the first-line setting in selected cases as well as in relapse. Next-generation sequencing for the identification of targetable mutations, evaluation of measurable residual disease, and risk stratification continue to be areas of active investigation. Recent advances in HCL have led to more effective therapeutics in the upfront and relapsed setting. Future efforts will focus on identifying patients with high-risk disease who require intensified regimens. Multicenter collaborations are the key to improving overall survival and quality of life in this rare disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.